Table 3.
Comparison of serum-tested biomarkers levels between groups
| Model A: Adjusted for age, gender, and BMI | Model B: Adjusted for age, gender, BMI, and physical activity | Model C: Adjusted for age, gender, BMI, and smoking status | Model D: Adjusted for age, gender, BMIMMP and SPARCC MRI SI joint inflammation score | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AxSpA vs WWPP | AxSpA vs DH | AxSpA vs HS | AxSpA vs WWPP | AxSpA vs DH | AxSpA vs HS | AxSpA vs WWPP | AxSpA vs DH | AxSpA vs HS | AxSpA vs WWPP | AxSpA vs DH | AxSpA vs HS | |
| C1M | < 0.0001 | 0.04 | < 0.0001 | < 0.0001 | 0.05 | < 0.0001 | 0.002 | 0.03 | < 0.0001 | 0.02 | 0.54 | 0.01 |
| C2M | 0.67 | 0.95 | 0.78 | 0.77 | 0.93 | 0.88 | 0.71 | 0.87 | 0.94 | 0.74 | 0.98 | 0.82 |
| T2CM | 1.00 | 0.96 | 0.93 | 1.00 | 0.96 | 0.89 | 0.98 | 0.86 | 0.73 | 0.99 | 1.00 | 0.64 |
| C3M | 0.59 | 0.14 | 0.11 | 0.62 | 0.18 | 0.32 | 0.55 | 0.07 | 0.03 | 1.00 | 0.91 | 0.99 |
| C4M | 0.02 | 0.01 | < 0.0001 | 0.02 | 0.02 | < 0.0001 | 0.03 | 0.01 | < 0.0001 | 0.18 | 0.28 | 0.09 |
| C6M | < 0.0001 | 0.38 | < 0.0001 | 0.001 | 0.44 | < 0.0001 | 0.002 | 0.29 | < 0.0001 | 0.01 | 0.78 | 0.01 |
| C10C | 0.90 | 0.75 | 0.79 | 0.89 | 0.73 | 0.73 | 0.78 | 0.81 | 0.71 | 0.72 | 0.48 | 0.48 |
| COL10NC | 1.00 | 0.99 | 0.66 | 1.00 | 0.99 | 0.76 | 1.00 | 0.97 | 0.93 | 0.97 | 0.74 | 1.00 |
| PROM | 0.66 | 0.94 | 0.11 | 0.82 | 0.94 | 0.16 | 0.62 | 0.95 | 0.11 | 0.63 | 0.90 | 0.17 |
| VICM | 0.04 | 0.01 | 0.002 | 0.05 | 0.01 | 0.003 | 0.11 | 0.002 | 0.002 | 0.22 | 0.16 | 0.17 |
| CRPM | 0.32 | 0.84 | 0.10 | 0.74 | 0.91 | 0.54 | 0.20 | 0.85 | 0.04 | 0.53 | 0.98 | 0.43 |
| PRO-C2 | 0.59 | 1.00 | 0.50 | 0.93 | 1.00 | 0.85 | 0.71 | 1.00 | 0.61 | 0.76 | 0.99 | 0.82 |
| PRO-C3 | 0.44 | 0.36 | 0.01 | 0.44 | 0.38 | 0.02 | 0.79 | 0.26 | 0.07 | 0.47 | 0.42 | 0.05 |
| PRO-C4 | < 0.0001 | 0.17 | < 0.0001 | < 0.0001 | 0.20 | 0.000 | 0.002 | 0.20 | < 0.0001 | 0.01 | 0.60 | < 0.0001 |
| PRO-C6 | 0.20 | 0.40 | 0.54 | 0.46 | 0.43 | 0.31 | 0.35 | 0.43 | 0.21 | 0.16 | 0.34 | 0.88 |
| C2M/PRO-C2 | 0.99 | 0.98 | 0.32 | 1.00 | 0.96 | 0.68 | 1.00 | 0.97 | 0.54 | 1.00 | 0.96 | 0.61 |
| C3M/PRO-C3 | 0.22 | 0.04 | 0.002 | 0.23 | 0.05 | 0.01 | 0.39 | 0.01 | 0.002 | 0.67 | 0.43 | 0.20 |
| C4M/PRO-C4 | 0.51 | 0.08 | 0.24 | 0.50 | 0.09 | 0.33 | 0.55 | 0.04 | 0.14 | 0.89 | 0.49 | 0.92 |
| C6M/PRO-C6 | < 0.0001 | 0.07 | 0.15 | < 0.0001 | 0.08 | 0.52 | < 0.0001 | 0.06 | 0.44 | < 0.0001 | 0.15 | 0.37 |
ANCOVA analysis between groups were performed. Comparisons that had statistical significance of p < 0.05 are highlighted in bold
Abbreviations: WWPP women with pelvic postpartum pain, DH disc herniation, HS healthy subjects, C1M metalloproteinase (MMP)-degraded type I collagen, C2M metalloproteinase (MMP)-degraded type II collagen, T2CM MMP-1 and MMP-13-mediated degradation of type II collagen, C3M MMP-degraded type III collagen, C4M MMP-degraded type IV collagen, C6M MMP-degraded type VI collagen, PROM MMP-1 and MMP-13-mediated degradation of prolargin, VICM citrullinated and MMP-degraded vimentin, CRPM C-reactive protein metabolite, C10C cathepsin-K mediated degradation of type X collagen, COL10NC NC domain of type X collagen, PRO-C2 pro-peptide of type II collagen, PRO-C3pro-peptide of type III collagen, PRO-C4 pro-peptide of type IV collagen, PRO-C6 pro-peptide of type VI collage